Cargando…
Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.
Two human primary liver cancer cell-lines, PLC/PRF/5 and Hep 3B, grown both in vitro and as xenografts in nude mice were used to evaluate the chemotherapeutic potential of a new quinazoline antifolate CB3717. Xenograft growth rate was followed both by serial serum alphafoetoprotein (AFP) measurement...
Autores principales: | Curtin, N. J., Harris, A. L., James, O. F., Bassendine, M. F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1986
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001363/ https://www.ncbi.nlm.nih.gov/pubmed/3008799 |
Ejemplares similares
-
Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.
por: Harding, M. J., et al.
Publicado: (1988) -
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
por: Cantwell, B. M., et al.
Publicado: (1988) -
Molecular docking studies on quinazoline antifolate derivatives as human thymidylate synthase inhibitors
por: Srivastava, Vivek, et al.
Publicado: (2010) -
Moderate antiproliferative effect of the antifolate CB3717 in the BN myeloid leukaemia model.
por: Ermens, A. A., et al.
Publicado: (1988) -
Toxicities of the antifoliate, CV3717
Publicado: (1988)